- Home
- SKYE vs FCEL Comparison
SKYE vs FCEL Comparison
Compare SKYE & FCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- FCEL
- Stock Information
- Founded
- SKYE 2012
- FCEL 1969
- Country
- SKYE United States
- FCEL United States
- Employees
- SKYE N/A
- FCEL N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- FCEL Industrial Machinery/Components
- Sector
- SKYE Health Care
- FCEL Energy
- Exchange
- SKYE Nasdaq
- FCEL Nasdaq
- Market Cap
- SKYE 108.5M
- FCEL 106.2M
- IPO Year
- SKYE N/A
- FCEL 1992
- Fundamental
- Price
- SKYE $4.07
- FCEL $6.59
- Analyst Decision
- SKYE Buy
- FCEL Hold
- Analyst Count
- SKYE 7
- FCEL 5
- Target Price
- SKYE $15.50
- FCEL $9.43
- AVG Volume (30 Days)
- SKYE 296.3K
- FCEL 2.5M
- Earning Date
- SKYE 11-06-2025
- FCEL 09-09-2025
- Dividend Yield
- SKYE N/A
- FCEL N/A
- EPS Growth
- SKYE N/A
- FCEL N/A
- EPS
- SKYE N/A
- FCEL N/A
- Revenue
- SKYE N/A
- FCEL $152,472,000.00
- Revenue This Year
- SKYE N/A
- FCEL $35.65
- Revenue Next Year
- SKYE N/A
- FCEL $38.42
- P/E Ratio
- SKYE N/A
- FCEL N/A
- Revenue Growth
- SKYE N/A
- FCEL 78.81
- 52 Week Low
- SKYE $1.14
- FCEL $3.58
- 52 Week High
- SKYE $6.13
- FCEL $16.10
- Technical
- Relative Strength Index (RSI)
- SKYE 59.48
- FCEL 74.59
- Support Level
- SKYE $3.96
- FCEL $3.93
- Resistance Level
- SKYE $4.35
- FCEL $4.53
- Average True Range (ATR)
- SKYE 0.29
- FCEL 0.48
- MACD
- SKYE 0.07
- FCEL 0.34
- Stochastic Oscillator
- SKYE 62.20
- FCEL 87.15
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.